Rituximab-induced lung disease: A systematic literature review.
about
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective reviewLung disease in rheumatoid arthritisThe spectrum of chronic CD8+ T-cell expansions: clinical features in 14 patients.Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report.Non-infectious pulmonary toxicity of rituximab: a systematic review.Drug induced interstitial lung disease.Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report.Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis.Thin-Section CT Characteristics and Longitudinal CT Follow-up of Chemotherapy Induced Interstitial Pneumonitis: A Retrospective Cohort Study.Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.Pulmonary toxicities from targeted therapies: a review.Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.Interstitial lung diseases: respiratory review of 2013.The safety of biologic therapies in RA-associated interstitial lung disease.Successful resolution of very severe hepatopulmonary syndrome following adult-to-adult living donor liver transplantation: Report of two cases.Management of pulmonary toxicity associated with targeted anticancer therapies.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Treatment and monitoring of hypersensitivity pneumonitis.Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy.Rituximab-induced bronchiolitis obliterans organizing pneumonia.Adverse events of monoclonal antibodies used for cancer therapy.Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases.Fatal rituximab-associated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome.Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.A case series of patients on chemotherapy with dyspnoea and pulmonary infiltrates.Rituximab-induced interstitial lung disease: five case reports.A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome.Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.Rituximab-induced pulmonary diseaseRituximab Induced Interstitial Lung Disease in Patients with Non-Hodgkin’s Lymphoma: A Clinical Study of Six Cases and Review of the Literature
P2860
Q26775753-6BA4BC2B-464E-4D0F-8588-45BB32E5CC41Q26853575-C8D2AA38-2DC0-4735-84D4-19D001BCE793Q31153816-0B8C7CF2-9104-4922-8C89-3DFB7024A87EQ33417132-16A08473-932C-4E54-A1C5-56B3C871358BQ34096300-655F4469-962E-46D5-B1BF-EE6E5EFFE5BFQ34641494-B27CFE85-4205-4E4A-8C9D-0ACABAF34EF1Q36330730-4E8C4A71-8455-4A5D-BE10-8949AE203A49Q36368134-EE3B405F-457A-4284-BF7B-218DE3DE4656Q36478155-463F259E-5C47-405C-8F15-8AA5C10B3FF4Q36664408-1AB8CA9A-F2C8-4B6E-9ECB-4D9FCB0540A1Q37955066-CB91752D-E7F8-418A-B875-93B4F5519406Q38014958-13ABE9BE-F242-4235-AFBE-624A98E8532EQ38090724-A116F765-BC8B-4409-97FD-2191645D03D2Q38136191-8D19F75A-4220-4E94-85F2-7B0F592E17C1Q38173669-34A8C6B8-D5E6-4207-AB2F-40C1711DBDC8Q38263781-C6B85C6D-BF45-49F5-B40F-A98900039F80Q38570532-C1D3731F-3291-4524-995C-F8E9721120F2Q38642378-3C86B370-17E7-41B2-865B-2777D1851EAFQ38818501-96D53D13-4795-459B-9A9E-6D8EEA050F9AQ38849896-944CDD08-DE3F-4E73-A0B2-E0406FAB52A7Q40124892-A6720646-4FE0-46D0-A6A5-AE45C8F2AADEQ40281058-81930D96-C3E2-46EC-A38B-E7F5B983210EQ40812370-F9CDEC7B-9AFF-4D06-A69F-E76FBE97B496Q40958100-C40CCEAC-5479-4D7A-A9AC-EBD950073F54Q41269163-D5058B79-323D-4D67-8A8E-E871522AED06Q42908395-5BF7A3AF-0E0A-4035-BE85-2234B6041B71Q43104543-7D599524-7F2E-49C8-8FEE-E6CC2FEAB247Q43192625-026E0066-9C57-48AE-8206-0DD153FEFD2DQ46191931-FD24B46B-BFFF-467B-B565-F3A72842F18CQ46858102-41D8C970-921C-4087-8F0E-6EEF27D7B51DQ52579907-A69F646B-DE3E-4767-AEEB-848089606207Q58043447-4996CFDE-7322-4A9C-A2A0-4991A25F6008Q59048666-49A3645B-3856-46F7-872E-3CC3828570B1
P2860
Rituximab-induced lung disease: A systematic literature review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rituximab-induced lung disease: A systematic literature review.
@en
Rituximab-induced lung disease: A systematic literature review.
@nl
type
label
Rituximab-induced lung disease: A systematic literature review.
@en
Rituximab-induced lung disease: A systematic literature review.
@nl
prefLabel
Rituximab-induced lung disease: A systematic literature review.
@en
Rituximab-induced lung disease: A systematic literature review.
@nl
P2093
P1476
Rituximab-induced lung disease: A systematic literature review.
@en
P2093
P304
P356
10.1183/09031936.00080209
P577
2009-07-16T00:00:00Z